C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC)

Historical Holders from Q4 2020 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CCCC on Nasdaq
Shares outstanding
71,366,920
Price per share
$2.22
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
52,538,995
Holdings value
$116,636,299
% of all portfolios
0%
Share change
-2,051,548
Value change
-$3,488,596
Average buys %
+0%
Average sells %
-0%
Number of holders
96
Price from insider filings
$1.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Point72 Asset Management, L.P. 9.9% $50,277,776 22,647,647 Point72 Asset Management, L.P. 17 Oct 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $20,959,588 +$20,959,588 9,441,256 RA Capital Management, L.P. 17 Oct 2025
Bain Capital Life Sciences Fund II, L.P. 6.2% $13,453,200 6,060,000 BCLS II Equity Opportunities, LP 17 Oct 2025
WASATCH ADVISORS LP 6.8% -34% $10,773,085 -$5,817,712 4,852,741 -35% Wasatch Advisors LP 30 Sep 2025
MORGAN STANLEY 6.7% +26% $7,315,590 +$1,419,222 4,750,383 +24% Morgan Stanley 30 Jun 2025
ORBIMED ADVISORS LLC 5% -23% $7,921,728 -$2,413,704 3,568,346 -23% OrbiMed Capital LLC 30 Sep 2025
BlackRock, Inc. 2.5% $2,705,184 1,756,613 BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) has 96 institutional shareholders filing 13F forms. They hold 52,538,995 shares of 71,366,920 outstanding shares (74%) .

Top 25 institutional shareholders own 68% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 9.9% 7,098,133 0% 3.2% $15,757,855
Soleus Capital Management, L.P. 9.9% 7,053,942 +1.1% 0.84% $15,659,751
ORBIMED ADVISORS LLC 7.3% 5,235,146 -23% 0.28% $11,622,024
MORGAN STANLEY 7% 4,972,032 +4.6% 0% $11,037,911
WASATCH ADVISORS LP 6.8% 4,852,741 -35% 0.06% $10,773,085
VANGUARD GROUP INC 4.5% 3,191,557 +5.7% 0% $7,085,256
BANK OF AMERICA CORP /DE/ 2.9% 2,053,162 +2.2% 0% $4,558,019
MILLENNIUM MANAGEMENT LLC 2.7% 1,934,225 +76% 0% $4,293,980
SILVERARC CAPITAL MANAGEMENT, LLC 2.7% 1,897,383 0.61% $4,212,190
BlackRock, Inc. 2.2% 1,595,639 -13% 0% $3,542,318
Bain Capital Life Sciences Investors, LLC 1.6% 1,111,910 0% 0.16% $2,468,440
RENAISSANCE TECHNOLOGIES LLC 1.3% 936,950 -14% 0% $2,080,029
TANG CAPITAL MANAGEMENT LLC 1.3% 900,000 0% 0.08% $1,998,000
TWO SIGMA INVESTMENTS, LP 1.2% 834,726 +22% 0% $1,853,092
TWO SIGMA ADVISERS, LP 1.1% 763,100 -6% 0% $1,694,082
GEODE CAPITAL MANAGEMENT, LLC 1% 725,304 -2.7% 0% $1,610,795
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.72% 515,437 +265% 0% $1,144,270
JACOBS LEVY EQUITY MANAGEMENT, INC 0.71% 503,145 +14% 0% $1,116,982
CITADEL ADVISORS LLC 0.67% 481,449 0% $1,068,817
GOLDMAN SACHS GROUP INC 0.64% 459,893 -48% 0% $1,020,962
Shay Capital LLC 0.59% 420,000 0.17% $932,400
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.49% 350,606 +5.6% 0% $778,345
DIMENSIONAL FUND ADVISORS LP 0.49% 349,289 -19% 0% $775,460
STATE STREET CORP 0.4% 287,373 0% 0% $637,968
Susquehanna Portfolio Strategies, LLC 0.38% 272,053 +114% 0.01% $603,958

Institutional Holders of C4 Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CCCC) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 52,538,995 $116,636,299 -$3,488,596 $2.22 96
2025 Q2 54,715,914 $78,242,864 -$14,672,713 $1.43 102
2025 Q1 64,100,740 $102,562,453 -$12,577,773 $1.60 113
2024 Q4 64,400,415 $231,841,689 -$9,805,100 $3.60 113
2024 Q3 64,180,724 $365,858,797 +$21,073,780 $5.70 121
2024 Q2 60,887,928 $281,302,488 +$7,123,709 $4.62 114
2024 Q1 58,176,311 $475,299,432 +$91,161,641 $8.17 103
2023 Q4 85,000 $480,250 $5.65 1
2023 Q3 34,586,251 $64,330,383 +$58,951 $1.86 81
2023 Q2 34,113,513 $93,827,140 -$9,383,416 $2.75 93
2023 Q1 37,322,746 $117,193,106 -$15,047,983 $3.14 115
2022 Q4 39,112,024 $230,744,584 -$9,769,306 $5.90 109
2022 Q3 39,293,405 $344,572,414 -$2,387,272 $8.77 109
2022 Q2 38,822,960 $292,705,242 -$38,906,919 $7.54 105
2022 Q1 36,525,343 $885,662,995 +$12,934,452 $24.26 115
2021 Q4 34,930,540 $1,123,813,979 -$4,994,205 $32.20 114
2021 Q3 34,463,769 $1,541,455,693 +$108,870,130 $44.68 111
2021 Q2 31,669,684 $1,199,070,921 +$211,475,628 $37.84 106
2021 Q1 25,076,254 $926,007,055 +$92,329,956 $36.99 82
2020 Q4 22,245,476 $728,255,975 +$703,285,064 $33.13 73